Early results with selected new therapies in development for follicular lymphoma
Studies . | Number of patients . | ORR . | CRR . | Main adverse events . |
---|---|---|---|---|
|
|
|
| Cytokine release syndrome and ICANS (essentially grade 1-2), cytopenias (20%-25% grade ≥3) |
| 80 | 95% | 81% | Cytokine release syndrome (7% grade ≥3), ICANS (15% grade ≥3), cytopenias |
Studies . | Number of patients . | ORR . | CRR . | Main adverse events . |
---|---|---|---|---|
|
|
|
| Cytokine release syndrome and ICANS (essentially grade 1-2), cytopenias (20%-25% grade ≥3) |
| 80 | 95% | 81% | Cytokine release syndrome (7% grade ≥3), ICANS (15% grade ≥3), cytopenias |
CRR, complete response rate; ICANS, immune effector cell–associated neurotoxicity syndrome; ORR, overall response rate.